Concord Biotech Secures USFDA Approval for ANDA of Tofacitinib Tablets
Concord Biotech Ltd has achieved a significant milestone in its global expansion, securing approval from the U.S. Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) pertaining to Tofacitinib Tablets, available in 5 mg and 10 mg strengths. The approval positions the company favorably to capitalize on key market opportunities within the United States and internationally.The USFDA granted the approval for the ANDA covering Tofacitinib Tablets. These tablets are intended for the treatment of a range of autoimmune conditions in adult patients, including Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, and Active polyarticular course juvenile idiopathic arthritis (pcJIA).
The successful regulatory clearance aligns with Concord Biotech's strategic goal of enhancing its product offerings and supporting long-term growth across the US and international markets. The U.S. market for Tofacitinib Tablets encompasses both strengths and is estimated to be approximately US$ 500 million, offering substantial commercial potential for the company.
This approval strengthens Concord Biotech's presence in the highly specialized therapeutic segment of autoimmune diseases within the lucrative North American market.
CONCORDBIO Stock Price Movement
Shares of Concord Biotech are rallying as of 10:11 AM, currently edging higher to ₹1340 after climbing 5.33% from market open. The stock maintains strong trading activity within the day's range, having accumulated a volume of 437,554 shares in live trading.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.